Meeting
2020 Gastrointestinal Cancers Symposium
Prognostic and predictive impact of primary tumor sidedness in first-line trials for advanced colorectal cancer: An analysis of 7,828 patients in the ARCAD database.
Authors
Jun Yin
Department of Health Science Research, Mayo Clinic, Rochester, MN
Jun Yin , Romain Cohen , Zhaohui Jin , Heshan Liu , Levi Pederson , Richard Adams , Tim Maughan , Alan P. Venook , Eric Van Cutsem , Chiara Cremolini , Niall Tebbut , Matt Seymour , Carsten Bokemeyer , Eduardo Diaz-Rubio , Harpreet Singh Wasan , Volker Heinemann , Aimery De Gramont , Qian Shi , Heinz-Josef Lenz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Anal and Colorectal Cancer
Track
Colorectal Cancer,Anal Cancer
Sub Track
Translational Research
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 188)
Abstract #
188
Poster Bd #
J8
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Sidedness and addition of chemotherapy associated with treatment outcomes of regorafenib for metastatic colorectal cancer (mCRC).
First Author: Tsung-Che Wu
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase 1b/2 study of VS-6766 in combination cetuximab in patients (pts) with advanced KRAS mt colorectal cancer (CRC).
First Author: Ardaman Shergill
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Anlotinib combined with mXELIRI as second-line treatment in advanced colorectal cancer pretreated with bevacizumab plus standard chemotherapy: A single-arm, phase IB/II study.
First Author: Xin Qu
Poster
2020 Gastrointestinal Cancers Symposium
Survival impact on regorafenib (REG) and trifluridine/tipiracil hydrochloride (FTD/TPI) for patients with metastatic colorectal cancer: Single institutional experience.
First Author: Keigo Chida